drugset / Trial / NCT05112263

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

NCT05112263

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomised trial plans to compare oral tofacitinib with intravenous cyclosporine in patients with acute severe ulcerative colitis who have failed to respond to intravenous steroids

Timeline

Start
2023-07-01
Primary completion
2025-12-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 4 mg/kg Intravenous
Subject Tofacitinib Small molecule 5 mg Oral

Indications